Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee

Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022…
Read More

Get A FREE Copy Of My Special Report
“Can Your Retirement Survive” Today!
There's Absolutely $0 Cost To You!
We Even Pay For Shipping & Handling!

This post contains affiliate links. If you use these links to buy something we may earn a commission. Thanks.”

You May Also Like